Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 35 | 33 | 35 | 43 | 40 |
| Accounts receivable | 17 | -338 | 163 | -465 | 428 |
| Accounts payable and accrued liabilities | 72 | 17 | 42 | -474 | 500 |
| Other Working Capital | -1,203 | -793 | -531 | -969 | 474 |
| Other Operating Activity | -500 | -2,823 | -5,776 | -4,764 | -5,129 |
| Operating Cash Flow | $-1,579 | $-3,904 | $-6,067 | $-6,629 | $-3,687 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -15 | -46 | -26 | -41 | N/A |
| Other Investing Activity | 69 | -38 | -5 | -7 | 0 |
| Investing Cash Flow | $54 | $-84 | $-31 | $-48 | $0 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -22 | -22 | -11 | -38 | -39 |
| Common Stock Issued | 891 | 1,555 | 0 | 3,914 | 3,624 |
| Other Financing Activity | 1,835 | 1,384 | 136 | 11,427 | 439 |
| Financing Cash Flow | $2,704 | $2,917 | $125 | $15,303 | $4,024 |
| Exchange Rate Effect | -56 | 9 | -128 | 84 | 28 |
| Beginning Cash Position | 3,885 | 4,947 | 11,048 | 2,338 | 1,973 |
| End Cash Position | 5,008 | 3,885 | 4,947 | 11,048 | 2,338 |
| Net Cash Flow | $1,179 | $-1,071 | $-5,973 | $8,626 | $337 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,579 | -3,904 | -6,067 | -6,629 | -3,687 |
| Capital Expenditure | -15 | -46 | -26 | -41 | N/A |
| Free Cash Flow | -1,594 | -3,950 | -6,093 | -6,670 | -3,687 |